🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Aviv Ladanie

Swiss Tropical and Public Health Institute

ORCID: 0000-0003-1050-3536

Also affiliated with University of Basel, University Hospital of Basel

Decision SciencesMathematicsEconomics, Econometrics and FinanceMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 4%percentile
0.899Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Trials(2018)10.1186/s13063-018-2877-z
Top 22%
0.899DataRank
Top 22%23 citations

Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more

Papers

Driven by 6 papers — median percentile 78. Top paper: “Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016”.

Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.24406
N/A
4.3DataRank · unranked
97 citations

Andreas M. Schmitt, Benjamin Speich, Florian Naudet, Arnav Agarwal, Tiago V. Pereira +12 more

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Trials(2018)10.1186/s13063-018-2877-z
Top 22%
0.899DataRank
Top 22%23 citations

Benjamin Speich, Florian Naudet, Arnav Agarwal, Francesco Sclafani, Juan Martin-Liberal +9 more

Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies

Journal of Clinical Epidemiology(2019)10.1016/j.jclinepi.2019.05.033
N/A
0.477DataRank · unranked
23 citations

Benjamin Speich, Matthias Briel, Francesco Sclafani, Heiner C. Bucher, Arnav Agarwal +5 more

Nonrandomized studies using causal-modeling may give different answers than RCTs: a meta-epidemiological study

Journal of Clinical Epidemiology(2020)10.1016/j.jclinepi.2019.10.012
N/A
0.442DataRank · unranked
18 citations

Aviv Ladanie, Kimberly Mc Cord, Heiner C. Bucher, Lars G. Hemkens, John P. A. Ioannidis +1 more

Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis

Journal of Clinical Epidemiology(2019)10.1016/j.jclinepi.2018.11.001
N/A
0.373DataRank · unranked
11 citations

Benjamin Speich, Aviv Ladanie, Heiner C. Bucher, Lars G. Hemkens, John P. A. Ioannidis +1 more

Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response

Journal of Clinical Epidemiology(2018)10.1016/j.jclinepi.2018.05.012
N/A
0DataRank · unranked
0 citations

Randall S. Stafford, Hannah Ewald, Heiner C. Bucher, Lars G. Hemkens, John P. A. Ioannidis +1 more